| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $985,537 ) |
| | 2025 | 2025 | BCN BIOSCIENCES LLC | 2265 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44AI177220 | Mitigation of Radiation Induced Gastrointestinal Syndrome. | 000 | 3 | NIH | 6/27/2025 | $985,537 |
|
| Issue Date FY: 2024 ( Subtotal = $1,005,819 ) |
| | 2024 | 2024 | BCN BIOSCIENCES LLC | 2265 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44AI177220 | Mitigation of Radiation Induced Gastrointestinal Syndrome. | 000 | 2 | NIH | 8/15/2024 | $1,005,819 |
|
| Issue Date FY: 2023 ( Subtotal = $1,034,934 ) |
| | 2023 | 2023 | BCN BIOSCIENCES LLC | 2265 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44AI177220 | Mitigation of Radiation Induced Gastrointestinal Syndrome. | 000 | 1 | NIH | 8/1/2023 | $1,034,934 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2020 | BCN BIOSCIENCES L.L.C. | 2265 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R43AI145784 | BCN057 as a mitigator of Radiation Induced Gastrointestinal Syndrome | 000 | 2 | NIH | 1/28/2022 | $0 |
| | 2022 | 2013 | BCN Biosciences L.L.C. | 2265 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | T01EP130002 | Project title not provided | 06 | 1 | ASPR | 6/13/2022 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $299,668 ) |
| | 2020 | 2020 | BCN BIOSCIENCES L.L.C. | 2265 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R43AI145784 | BCN057 as a mitigator of Radiation Induced Gastrointestinal Syndrome | 000 | 2 | NIH | 6/8/2020 | $299,668 |
|
| Issue Date FY: 2019 ( Subtotal = $299,857 ) |
| | 2019 | 2019 | BCN BIOSCIENCES L.L.C. | 2265 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R43AI145784 | BCN057 as a mitigator of Radiation Induced Gastrointestinal Syndrome | 000 | 1 | NIH | 6/27/2019 | $299,857 |
| | 2019 | 2013 | Bcn Biosciences L.L.C. | 2265 E Foothill Blvd | Pasadena | CA | 91107-3658 | LOS ANGELES | USA | T01EP130002 | Project title not provided | 05 | 1 | ASPR | 9/20/2019 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $0 ) |
| | 2017 | 2014 | BCN BIOSCIENCES L.L.C. | 2265 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R43CA180316 | A dual acting drug for enhancing radiotherapeutic benefit | 000 | 1 | NIH | 10/24/2016 | $0 |
|
| Issue Date FY: 2014 ( Subtotal = $209,208 ) |
| | 2014 | 2014 | BCN BIOSCIENCES LLC | 2275 EAST FOOTHILL BOULEVARD | PASADENA | CA | 91107 | LOS ANGELES | USA | R43CA180316 | A dual acting drug for enhancing radiotherapeutic benefit | 000 | 1 | NIH | 5/19/2014 | $184,208 |
| | 2014 | 2014 | BCN BIOSCIENCES LLC | 2275 EAST FOOTHILL BOULEVARD | PASADENA | CA | 91107 | LOS ANGELES | USA | R43CA180316 | A dual acting drug for enhancing radiotherapeutic benefit | 001 | 1 | NIH | 9/12/2014 | $25,000 |
|
| Issue Date FY: 2013 ( Subtotal = $4,016,035 ) |
| | 2013 | 2013 | BCN BIOSCIENCES LLC | 2275 EAST FOOTHILL BOULEVARD | PASADENA | CA | 91107 | LOS ANGELES | USA | T01EP130002 | Project title not provided | 00 | 1 | ASPR | 8/20/2013 | $4,016,035 |
|
| Issue Date FY: 2010 ( Subtotal = $160,735 ) |
| | 2010 | 2010 | BCN BIOSCIENCES LLC | 2275 EAST FOOTHILL BOULEVARD | PASADENA | CA | 91107 | LOS ANGELES | USA | R43CA141728 | A NOVEL TARGETED THERAPY | 000 | 1 | NIH | 9/3/2010 | $160,735 |
|
| Issue Date FY: 2009 ( Subtotal = $0 ) |
| | 2009 | 2008 | BCN BIOSCIENCES LLC | 2275 EAST FOOTHILL BOULEVARD | PASADENA | CA | 91107 | LOS ANGELES | USA | R43CA132405 | TRANSLATIONAL RESEARCH IN A NOVEL ANTI CANCER AGENT | 000 | 1 | NIH | 10/17/2008 | $0 |
|
| Issue Date FY: 2008 ( Subtotal = $229,717 ) |
| | 2008 | 2008 | BCN BIOSCIENCES LLC | 2275 EAST FOOTHILL BOULEVARD | PASADENA | CA | 91107 | LOS ANGELES | USA | R43CA132405 | TRANSLATIONAL RESEARCH IN A NOVEL ANTI CANCER AGENT | 000 | 1 | NIH | 8/13/2008 | $99,510 |
| | 2008 | 2008 | BCN BIOSCIENCES LLC | 2275 EAST FOOTHILL BOULEVARD | PASADENA | CA | 91107 | LOS ANGELES | USA | R43CA114876 | BOTANICAL-DERIVED DRUG DISCOVERY FOR CANCER THERAPY | 000 | 1 | NIH | 9/22/2008 | $130,207 |
|
|
